Literature DB >> 28866745

Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Laura Nuño-Nuño1, Beatriz Esther Joven2, Patricia E Carreira2, Valentina Maldonado-Romero3, Carmen Larena-Grijalba3, Irene Llorente Cubas4, Eva Gloria Tomero4, María Carmen Barbadillo-Mateos5, Paloma García De la Peña Lefebvre6, Lucía Ruiz-Gutiérrez7, Juan Carlos López-Robledillo7, Henry Moruno-Cruz8, Ana Pérez8, Tatiana Cobo-Ibáñez9, Raquel Almodóvar González10, Leticia Lojo11, María Jesús García De Yébenes12, Francisco Javier López-Longo13.   

Abstract

The present study was undertaken to assess mortality, causes of death, and associated prognostic factors in a large cohort of patients diagnosed with idiopathic inflammatory myositis (IIM) from Spain. A retrospective longitudinal study was carried out in 467 consecutive patients with IIM, identified from 12 medical centers. Patients were classified as primary polymyositis, primary dermatomyositis (DM), overlap myositis, cancer-associated myositis (CAM), and juvenile idiopathic inflammatory myopathies. A total of 113 deaths occurred (24%) after a median follow-up time of 9.7 years. In the overall cohort, the 2-, 5-, and 10-year survival probabilities were 91.9, 86.7, and 77%, respectively. Main causes of death were infections and cancer (24% each). Multivariate model revealed that CAM (HR = 24.06), OM (HR = 12.00), DM (HR = 7.26), higher age at diagnosis (HR = 1.02), severe infections (HR = 3.66), interstitial lung disease (HR = 1.61), and baseline elevation of acute phase reactants (HR = 3.03) were associated with a worse prognosis, while edema of the hands (HR = 0.39), female gender (HR = 0.39), and longer disease duration (HR = 0.73) were associated with a better prognosis. The standardized mortality ratio was 1.56 (95% CI 1.28-1.87) compared to the Spanish general population. Our findings indicate that IIM has a high long-term mortality, with an excess of mortality compared to the Spanish population. A more aggressive therapy may be required in IIM patients presenting with poor predictive factors.

Entities:  

Keywords:  Idiopathic inflammatory myositis; Overlap myositis; Prognosis; Survival

Mesh:

Year:  2017        PMID: 28866745     DOI: 10.1007/s00296-017-3799-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  37 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis.

Authors:  I Marie; E Hachulla; P Y Hatron; M F Hellot; H Levesque; B Devulder; H Courtois
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

Review 3.  Incidence and prevalence of inflammatory myopathies: a systematic review.

Authors:  Alain Meyer; Nicolas Meyer; Mickael Schaeffer; Jacques-Eric Gottenberg; Bernard Geny; Jean Sibilia
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Why do patients with myositis die? A retrospective analysis of a single-centre cohort.

Authors:  Marta Amaral Silva; Estefania Cogollo; David A Isenberg
Journal:  Clin Exp Rheumatol       Date:  2016-08-02       Impact factor: 4.473

Review 6.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

7.  Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases.

Authors:  J Benbassat; D Gefel; K Larholt; S Sukenik; V Morgenstern; A Zlotnick
Journal:  Arthritis Rheum       Date:  1985-03

8.  Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.

Authors:  D Alarcón-Segovia; M H Cardiel
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

9.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

Review 10.  Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis.

Authors:  Xin Lu; Hanbo Yang; Xiaoming Shu; Fang Chen; Yinli Zhang; Sigong Zhang; Qinglin Peng; Xiaolan Tian; Guochun Wang
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

View more
  6 in total

1.  Prognostic factors for steroid-free remission in patients with idiopathic inflammatory myopathies: importance of anthropometric measurements.

Authors:  Jung Sun Lee; Jung Eun Lee; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Ji Seon Oh; Yong-Gil Kim
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-16       Impact factor: 5.346

2.  A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis.

Authors:  Q-L Peng; Y-M Zhang; L Liang; X Liu; L-F Ye; H-B Yang; L Zhang; X-M Shu; X Lu; G-C Wang
Journal:  Clin Exp Immunol       Date:  2019-12-18       Impact factor: 4.330

3.  Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia.

Authors:  Alojzija Hočevar; Andrej Viršček; Monika Krošel; Suzana Gradišnik; Žiga Rotar; Matija Tomšič; Iztok Holc
Journal:  Front Med (Lausanne)       Date:  2021-12-20

Review 4.  Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.

Authors:  Erin M Wilfong; Rohit Aggarwal
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-12-09       Impact factor: 3.625

5.  A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Authors:  Alexander G S Oldroyd; Andrew B Allard; Jeffrey P Callen; Hector Chinoy; Lorinda Chung; David Fiorentino; Michael D George; Patrick Gordon; Kate Kolstad; Drew J B Kurtzman; Pedro M Machado; Neil J McHugh; Anna Postolova; Albert Selva-O'Callaghan; Jens Schmidt; Sarah Tansley; Ruth Ann Vleugels; Victoria P Werth; Rohit Aggarwal
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

6.  Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.

Authors:  Zhiqian Bai; Guifen Shen; Lingli Dong
Journal:  Int J Rheum Dis       Date:  2021-05-24       Impact factor: 2.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.